{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T13:22:23Z","timestamp":1786972943886,"version":"build-2736575974"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T00:00:00Z","timestamp":1645833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"The National Cancer Institute Gastrointestinal Cancer Center Specialized Programs of Research Excellence (SPORE) Career Development Award","award":["5P50CA127003-08"],"award-info":[{"award-number":["5P50CA127003-08"]}]},{"name":"Dr McCleary\u2019s effort"},{"name":"The ARCAD Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>We evaluated the time to progression (TTP) and survival outcomes of second-line therapy for metastatic colorectal cancer among adults aged 70 years and older compared with younger adults following progression on first-line clinical trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Associations between clinical and disease characteristics, time to initial progression, and rate of receipt of second-line therapy were evaluated. TTP and overall survival (OS) were compared between older and younger adults in first- and second-line trials by Cox regression, adjusting for age, sex, Eastern Cooperative Oncology Group Performance Status, number of metastatic sites and presence of metastasis in the lung, liver, or peritoneum. All statistical tests were 2-sided.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Older adults comprised 16.4% of patients on first-line trials (870 total older adults aged &amp;gt;70 years; 4419 total younger adults aged \u226470 years, on first-line trials). Older adults and those with Eastern Cooperative Oncology Group Performance Status &amp;gt;0 were less likely to receive second-line therapy than younger adults. Odds of receiving second-line therapy decreased by 11% for each additional decade of life in multivariable analysis (odds ratio = 1.11, 95% confidence interval = 1.02 to 1.21, P = .01). Older and younger adults enrolled in second-line trials experienced similar median TTP and median OS (median TTP = 5.1 vs 5.2 months, respectively; median OS = 11.6 vs 12.4 months, respectively).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Older adults were less likely to receive second-line therapy for metastatic colorectal cancer, though we did not observe a statistical difference in survival outcomes vs younger adults following second-line therapy. Further study should examine factors affecting decisions to treat older adults with second-line therapy. Inclusion of geriatric assessment may provide better criteria regarding the risks and benefits of second-line therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jncics\/pkac014","type":"journal-article","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T20:11:16Z","timestamp":1645819876000},"source":"Crossref","is-referenced-by-count":5,"title":["Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2377-8301","authenticated-orcid":false,"given":"Nadine J","family":"McCleary","sequence":"first","affiliation":[{"name":"Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William S","family":"Harmsen","sequence":"additional","affiliation":[{"name":"Department of Health Science Research, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellana","family":"Haakenstad","sequence":"additional","affiliation":[{"name":"Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M","family":"Cleary","sequence":"additional","affiliation":[{"name":"Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A","family":"Meyerhardt","sequence":"additional","affiliation":[{"name":"Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6624-0782","authenticated-orcid":false,"given":"John","family":"Zalcberg","sequence":"additional","affiliation":[{"name":"Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3915-7243","authenticated-orcid":false,"given":"Richard","family":"Adams","sequence":"additional","affiliation":[{"name":"Cardiff University and Velindre Cancer Centre, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9341-6499","authenticated-orcid":false,"given":"Axel","family":"Grothey","sequence":"additional","affiliation":[{"name":"West Cancer Center and Research Institute, OneOncology, Germantown, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7764-673X","authenticated-orcid":false,"given":"Alberto F","family":"Sobrero","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Ospedale San Martino, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6372-1230","authenticated-orcid":false,"given":"Eric","family":"Van Cutsem","sequence":"additional","affiliation":[{"name":"University of Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0308-8223","authenticated-orcid":false,"given":"Richard M","family":"Goldberg","sequence":"additional","affiliation":[{"name":"West Virginia University Cancer Institute and the Mary Babb Randolph Cancer Center, Morgantown, WV, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4969-2303","authenticated-orcid":false,"given":"Marc","family":"Peeters","sequence":"additional","affiliation":[{"name":"Department of Oncology, Antwerp University Hospital, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2495-8139","authenticated-orcid":false,"given":"Josep","family":"Tabernero","sequence":"additional","affiliation":[{"name":"Vall d\u2019Hebron University Hospital and Institute of Oncology (VHIO), Institute of Oncology Barcelona-Quiron, UVic-UCC, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2441-9629","authenticated-orcid":false,"given":"Matt","family":"Seymour","sequence":"additional","affiliation":[{"name":"NIHR Clinical Research Network, Leeds, UK"},{"name":"St. James\u2019s Hospital and University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8353-4670","authenticated-orcid":false,"given":"Leonard B","family":"Saltz","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce J","family":"Giantonio","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Arnold","sequence":"additional","affiliation":[{"name":"Instituto CUF de Oncologia, Lisbon, Portugal"},{"name":"Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mace L","family":"Rothenberg","sequence":"additional","affiliation":[{"name":"Global Product Development, Pfizer Inc, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1550-1978","authenticated-orcid":false,"given":"Miriam","family":"Koopman","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Medical Center Utrecht, University of Urtrecht, Utrecht, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Joachim","family":"Schmoll","sequence":"additional","affiliation":[{"name":"Klinik fur Innere Med IV, University Clinic Halle (Saale), Halle, Germany"},{"name":"Martin Luther University, Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry C","family":"Pitot","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo M","family":"Hoff","sequence":"additional","affiliation":[{"name":"Centro de Oncologia de Brasilia do Sirio Libanes-Unidade Lago Sul, Siro Libanes, Brazil"},{"name":"Universidade de S\u00e3o Paulo Instituto do Cancer do Estado de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2613-5168","authenticated-orcid":false,"given":"Niall","family":"Tebbutt","sequence":"additional","affiliation":[{"name":"University of Sydney Medical School, Sydney, Australia"},{"name":"Austin Health, Heidelberg, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Masi","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Souglakos","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6071-7810","authenticated-orcid":false,"given":"Carsten","family":"Bokemeyer","sequence":"additional","affiliation":[{"name":"Universitatsklinikum Hamburg-Eppendorf, Hamburg-Eppendorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1349-3321","authenticated-orcid":false,"given":"Volker","family":"Heinemann","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Comprehensive Cancer Center Munich, University Hospital, LMU Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0489-4756","authenticated-orcid":false,"given":"Takayuki","family":"Yoshino","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital East, Kashiwa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoist","family":"Chibaudel","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Institut Franco-Britannique, Levallois-Perret, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7940-9877","authenticated-orcid":false,"given":"Aimery","family":"deGramont","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Institut Franco-Britannique, Levallois-Perret, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4640-8832","authenticated-orcid":false,"given":"Qian","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Health Science Research, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4146-6192","authenticated-orcid":false,"given":"Stuart M","family":"Lichtman","sequence":"additional","affiliation":[{"name":"NIHR Clinical Research Network, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,2,26]]},"reference":[{"key":"2022032105001856800_pkac014-B1","first-page":"1029","author":"Bluethmann","year":"2016"},{"key":"2022032105001856800_pkac014-B2","volume-title":"Cancer Stat Facts: Colorectal Cancer","author":"National Cancer Institute Division of Cancer Control and Population Sciences","year":"2020"},{"issue":"1","key":"2022032105001856800_pkac014-B3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1001\/jamasurg.2014.1756","article-title":"Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010","volume":"150","author":"Bailey","year":"2015","journal-title":"JAMA Surg"},{"key":"2022032105001856800_pkac014-B4","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.2147\/CMAR.S166548","article-title":"Proximal shift of colorectal cancer with increasing age in different ethnicities","volume":"10","author":"Yang","year":"2018","journal-title":"CMAR"},{"key":"2022032105001856800_pkac014-B5","volume-title":"Cancer Facts and Figures 2020","author":"American Cancer Society","year":"2020"},{"issue":"35","key":"2022032105001856800_pkac014-B6","doi-asserted-by":"crossref","first-page":"5721","DOI":"10.1200\/JCO.2008.17.7147","article-title":"Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741","volume":"26","author":"Sanoff","year":"2008","journal-title":"J Clin Oncol"},{"issue":"6","key":"2022032105001856800_pkac014-B7","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1200\/JCO.2011.38.9650","article-title":"Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer","volume":"30","author":"Jeffrey","year":"2012","journal-title":"J Clin Oncol"},{"issue":"15","key":"2022032105001856800_pkac014-B8","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1002\/cncr.31552","article-title":"Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer","volume":"124","author":"Sanoff","year":"2018","journal-title":"Cancer"},{"issue":"9","key":"2022032105001856800_pkac014-B9","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1200\/JCO.2007.14.0509","article-title":"Irinotecan\/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials","volume":"26","author":"Jean Yves Douillard","year":"2008","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"2022032105001856800_pkac014-B10","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1200\/jco.2009.27.15_suppl.4010","article-title":"Impact of older age on the efficacy of newer adjuvant therapies in&gt; 12,500 patients (pts) with stage II\/III colon cancer: findings from the ACCENT Database","volume":"27","author":"Jackson McCleary","year":"2009","journal-title":"J Clin Oncol"},{"key":"2022032105001856800_pkac014-B11","volume-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Colon Cancer","author":"National Comprehensive Cancer Network","year":"2020"},{"key":"2022032105001856800_pkac014-B12","volume-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Rectal Cancer","author":"National Comprehensive Cancer Network","year":"2020"},{"issue":"8","key":"2022032105001856800_pkac014-B13","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol"},{"issue":"suppl 18","key":"2022032105001856800_pkac014-B14","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1200\/jco.2007.25.18_suppl.4007","article-title":"Oxaliplatin\/5FU\/LV in adjuvant colon cancer: updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years","volume":"25","author":"De Gramont","year":"2007","journal-title":"J Clin Oncol"},{"issue":"28","key":"2022032105001856800_pkac014-B15","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1200\/JCO.2011.36.4539","article-title":"Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses","volume":"29","author":"Yothers","year":"2011","journal-title":"J Clin Oncol"},{"issue":"9","key":"2022032105001856800_pkac014-B16","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/annonc\/mdh344","article-title":"Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials","volume":"15","author":"Folprecht","year":"2004","journal-title":"Ann Oncol"},{"issue":"25","key":"2022032105001856800_pkac014-B17","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1200\/JCO.2006.06.9039","article-title":"Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil\/leucovorin administered bimonthly in elderly patients with colorectal cancer","volume":"24","author":"Goldberg","year":"2006","journal-title":"J Clin Oncol"},{"issue":"12","key":"2022032105001856800_pkac014-B18","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1002\/cncr.23091","article-title":"FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study","volume":"110","author":"Figer","year":"2007","journal-title":"Cancer"},{"issue":"9779","key":"2022032105001856800_pkac014-B19","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/S0140-6736(11)60399-1","article-title":"Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial","volume":"377","author":"Seymour","year":"2011","journal-title":"Lancet"},{"issue":"9","key":"2022032105001856800_pkac014-B20","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1200\/JCO.2007.14.0509","article-title":"Irinotecan\/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials","volume":"26","author":"Folprecht","year":"2008","journal-title":"J Clin Oncol"},{"issue":"11","key":"2022032105001856800_pkac014-B21","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1093\/annonc\/mdp233","article-title":"Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study","volume":"20","author":"Van Cutsem","year":"2009","journal-title":"Ann Oncol"},{"key":"2022032105001856800_pkac014-B22","first-page":"26","article-title":"Safety and effectiveness of bevacizumab (BV) and chemotherapy (CT) in elderly patients with metastatic colorectal cancer (mCRC): results from the BRiTE observational cohort study","volume":"19","author":"Kozloff","year":"2008","journal-title":"Ann Oncol"},{"issue":"31","key":"2022032105001856800_pkac014-B23","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","article-title":"Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study","volume":"28","author":"Douillard","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"2022032105001856800_pkac014-B24","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/bjc.2011.554","article-title":"Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer","volume":"106","author":"Jehn","year":"2012","journal-title":"Br J Cancer"},{"issue":"9","key":"2022032105001856800_pkac014-B25","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s00432-012-1229-8","article-title":"Anti-EGFR (cetuximab) combined with irinotecan for treatment of elderly patients with metastatic colorectal cancer (mCRC)","volume":"138","author":"Abdelwahab","year":"2012","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"2022032105001856800_pkac014-B26","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.critrevonc.2009.11.005","article-title":"First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD)","volume":"77","author":"Sastre","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"2022032105001856800_pkac014-B27","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1634\/theoncologist.2011-0406","article-title":"First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study","volume":"17","author":"Sastre","year":"2012","journal-title":"Oncologist"},{"key":"2022032105001856800_pkac014-B28","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ctrv.2016.02.006","article-title":"Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: a systematic review and meta-analysis","volume":"45","author":"Nishijima","year":"2016","journal-title":"Cancer Treat Rev"},{"issue":"22","key":"2022032105001856800_pkac014-B29","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1001\/jama.291.22.2720","article-title":"Participation in cancer clinical trials: race-, sex-, and age-based disparities","volume":"291","author":"Murthy","year":"2004","journal-title":"JAMA"},{"issue":"3","key":"2022032105001856800_pkac014-B30","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1634\/theoncologist.10-3-198","article-title":"Never too old? Age should not be a barrier to enrollment in cancer clinical trials","volume":"10","author":"Aapro","year":"2005","journal-title":"Oncologist"},{"issue":"24","key":"2022032105001856800_pkac014-B31","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1200\/JCO.2014.55.1960","article-title":"Refining the chemotherapy approach for older patients with colon cancer","volume":"32","author":"McCleary","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"2022032105001856800_pkac014-B32","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cger.2015.08.005","article-title":"Long term toxicity of cancer treatment in older patients","volume":"32","author":"Shahrokni","year":"2016","journal-title":"Clin Geriatr Med"},{"issue":"14","key":"2022032105001856800_pkac014-B33","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO.2007.10.6559","article-title":"Comprehensive geriatric assessment for older patients with cancer","volume":"25","author":"Extermann","year":"2007","journal-title":"J Clin Oncol"},{"key":"2022032105001856800_pkac014-B34","first-page":"1290","article-title":"Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401","volume-title":"J Clin Oncol","author":"Hurria","year":"2011"},{"key":"2022032105001856800_pkac014-B35","first-page":"e047376","article-title":"Cancer Aging Research Group (CARG) score in older adults undergoing curative intent chemotherapy: a prospective cohort study","volume-title":"BMJ Open","author":"Ostwal","year":"2021"},{"key":"2022032105001856800_pkac014-B36","first-page":"7","article-title":"Cancer and aging; preparing for silver tsunami","volume":"3","author":"Mahmoudzadeh","year":"2015","journal-title":"J Geriatr Palliat Care"},{"issue":"6","key":"2022032105001856800_pkac014-B37","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/cncr.29125","article-title":"Impact of colorectal cancer diagnosis and treatment on health-related quality of life among older Americans: a population-based, case-control study","volume":"121","author":"Quach","year":"2015","journal-title":"Cancer"},{"key":"2022032105001856800_pkac014-B38","volume-title":"Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims","author":"Food and Drug Administration","year":"2009"},{"issue":"8","key":"2022032105001856800_pkac014-B39","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jamaoncol.2015.2639","article-title":"Validity and reliability of the US National Cancer Institute\u2019s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"1","author":"Dueck","year":"2015","journal-title":"JAMA Oncol"},{"issue":"2","key":"2022032105001856800_pkac014-B40","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA"},{"key":"2022032105001856800_pkac014-B41","author":"National Cancer Institute Division of Cancer Control and Population Sciences. Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events","year":"2020"},{"issue":"22","key":"2022032105001856800_pkac014-B42","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","article-title":"Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology","volume":"36","author":"Mohile","year":"2018","journal-title":"J Clin Oncol"},{"key":"2022032105001856800_pkac014-B43","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejca.2018.05.010","article-title":"Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: supported by the ARCAD Group","volume":"100","author":"Goey","year":"2018","journal-title":"Eur J Cancer"},{"issue":"10","key":"2022032105001856800_pkac014-B44","doi-asserted-by":"crossref","first-page":"e0223449","DOI":"10.1371\/journal.pone.0223449","article-title":"The accumulation of deficits approach to describe frailty","volume":"14","author":"Lachmann","year":"2019","journal-title":"PLoS One"}],"container-title":["JNCI Cancer Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jncics\/advance-article-pdf\/doi\/10.1093\/jncics\/pkac014\/42620166\/pkac014.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/6\/2\/pkac014\/42956352\/pkac014.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/6\/2\/pkac014\/42956352\/pkac014.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T05:01:13Z","timestamp":1647838873000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncics\/article\/doi\/10.1093\/jncics\/pkac014\/6537541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,26]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jncics\/pkac014","relation":{},"ISSN":["2515-5091"],"issn-type":[{"value":"2515-5091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,4,1]]},"published":{"date-parts":[[2022,2,26]]},"article-number":"pkac014"}}